JSPR Phase 2 readout: a negative outcome, -8.7%

On April 1, 2026, Briquilimab — Jasper Therapeutics, Inc. (Chronic Spontaneous Urticaria) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -8.7% in the window around the event. It had already run -22.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.